Jan 05, 2022
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference
Corporate
Jan 04, 2022
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service
Corporate
Dec 14, 2021
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer
Corporate
Oct 18, 2021
Myriad Genetics Names Pamela Wong as Chief Legal Officer
Corporate
Sep 13, 2021
Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp
Corporate
Jul 21, 2021
Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities
Corporate
Jul 01, 2021
Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions
Corporate
Jun 16, 2021
Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics
Corporate
Jun 04, 2021
Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
Corporate
Jun 01, 2021
Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
Corporate
May 24, 2021
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
Corporate
May 20, 2021
Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business
Corporate
May 05, 2021
Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference
Corporate
May 03, 2021
Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp
Corporate
May 03, 2021
Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day
Corporate